BUZZ-WuXi AppTec falls as US Senate bill on Chinese biotech firms moves forward

Reuters03-07

** Hong Kong shares of WuXi AppTec fall as much as 20.6% to HK$45, their lowest since Feb 21

** Stock last down 11.9%; second biggest pct loser in Hang Seng Index and Hang Seng Composite Index

** Shanghai shares opens down a maximum 10%

** The U.S. Senate's homeland security committee voted on Wednesday to approve a bill that could restrict business with Chinese biotech companies like BGI and WuXi AppTec on national security grounds

** The bill is designed to keep Americans' personal health and genetic information from foreign adversaries

** The bill has spurred deep concern among investors, driving a sell-off in the shares of WuXi AppTec when news of its introduction first reached Chinese markets last month

** Shares of WuXi Biologics , an affilate of WuXi AppTec, fall as much as 18.9% to HK$17.64, lowest since Feb 21

** Stock of WuXi XDC , a unit of WuXi Biologics, drop 18.8% to HK$18.84, lowest since March 1

** Hong Kong's healthcare index falls 2.4%, while Hang Seng Composite Index and Hang Seng Index both slip 0.1%

** Hong Kong stock of WuXi AppTec drops 38.6% YTD, WuXi Biologics down 39.1% YTD, WuXi XDC down 36.7% YTD

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment